| Literature DB >> 31668804 |
Eytan Herzig1, Kaman Chan Kim2, Thomas A Packard1, Noam Vardi3, Roland Schwarzer1, Andrea Gramatica1, Steven G Deeks4, Steven R Williams2, Kyle Landgraf2, Nigel Killeen2, David W Martin2, Leor S Weinberger5, Warner C Greene6.
Abstract
Current approaches to reducing the latent HIV reservoir entail first reactivating virus-containing cells to become visible to the immune system. A critical second step is killing these cells to reduce reservoir size. Endogenous cytotoxic T-lymphocytes (CTLs) may not be adequate because of cellular exhaustion and the evolution of CTL-resistant viruses. We have designed a universal CAR-T cell platform based on CTLs engineered to bind a variety of broadly neutralizing anti-HIV antibodies. We show that this platform, convertibleCAR-T cells, effectively kills HIV-infected, but not uninfected, CD4 T cells from blood, tonsil, or spleen and only when armed with anti-HIV antibodies. convertibleCAR-T cells also kill within 48 h more than half of the inducible reservoir found in blood of HIV-infected individuals on antiretroviral therapy. The modularity of convertibleCAR-T cell system, which allows multiplexing with several anti-HIV antibodies yielding greater breadth and control, makes it a promising tool for attacking the latent HIV reservoir.Entities:
Keywords: CAR-T; HIV latency; MicAbody; T cell therapy; bNAb; broadly neutralizing HIV antibodies; convertibleCAR-T; reduce-and-control; reservoir; shock-and-kill
Mesh:
Substances:
Year: 2019 PMID: 31668804 PMCID: PMC6922308 DOI: 10.1016/j.cell.2019.10.002
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582